Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;113:891-897
doi: 10.1161/CIRCULATIONAHA.105.569657
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baim, D. S.
Right arrow Articles by Kaplan, A. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baim, D. S.
Right arrow Articles by Kaplan, A. V.
Related Collections
Right arrow Health policy and outcome research
Right arrow AHA Statements and Guidelines

(Circulation. 2006;113:891-897.)
© 2006 American Heart Association, Inc.


Special Report

Postmarket Surveillance for Drug-Eluting Coronary Stents

A Comprehensive Approach

Donald S. Baim, MD; Roxana Mehran, MD; Dean J. Kereiakes, MD; Thomas P. Gross, MD, MPH; Michael Simons, MD; David Malenka, MD; Aaron V. Kaplan, MD

From the Cardiology Section, Brigham and Women’s Hospital, Boston, Mass (D.S.B.); Cardiovascular Research Foundation and Columbia University, New York, NY (R.M.); Heart Center/Lindner Center at the Christ Hospital, Cincinnati, Ohio (D.J.K.); Center for Devices and Radiological Health, US Food and Drug Administration, Rockville, Md (T.P.G.); and Cardiology Section, Dartmouth Medical School and Dartmouth-Hitchcock Medical Center, Lebanon, NH (M.S., D.M., A.V.K.).

Correspondence to Aaron V. Kaplan, MD, Cardiology Section, Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr, Lebanon, NH 03756–0001. E-mail aaron.v.kaplan@hitchock.org


Key Words: angioplasty • coronary disease • postmarket surveillance • regulatory policy • stents


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 


*    Introduction
 
The development and introduction of new medical devices have radically changed the practice of medicine. No area of medicine has been affected more than cardiology, with new devices facilitating the effective treatment of coronary artery disease (percutaneous coronary interventions [PCIs]/stents), valvular heart disease (mechanical and bioprosthetic valves), and electrophysiological disorders (pacemakers and automatic implantable cardiodefibrillators). In addition to fueling the growth of the medical device industry, this explosion of technology has driven the development of new medical subspecialties, eg, interventional cardiology and electrophysiology. Other areas of medicine, including orthopedics and general surgery, have witnessed similar transformations. The current regulatory pathway for a significant-risk first-in-class medical device is typically a long, expensive, and risky process, culminating in a pivotal trial designed to demonstrate safety and efficacy. The pivotal trial phase is typically the most time-consuming and costly phase of the process. In the United States, medical devices are regulated by the Center for Devices and Radiological Health at the Food and Drug Administration (FDA), which has been charged by Congress to seek the "least burdensome means" when determining the scope of data required to evaluate the safety and efficacy necessary for device approval.1 Thus, pivotal trials by intention are designed to select patient cohorts most likely to demonstrate procedural benefit while limiting patient/study subject risk within the shortest time frame that can provide meaningful data. The realities of logistics, time, and resources limit the size and duration of most new device trials to 800 to 1500 patients, limiting the power of . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
HeartHome page
N Melikian and W Wijns
Drug-eluting stents: a critique
Heart, February 1, 2008; 94(2): 145 - 152.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. J. Kereiakes
Does Clopidogrel Each Day Keep Stent Thrombosis Away?
JAMA, January 10, 2007; 297(2): 209 - 211.
[Full Text] [PDF]